AHA report demonstrates benefits of 340B program
The AHA May 25 published a report on the 340B Drug Pricing Program, its history and value to hospitals and patients, and details on 340B contract pharmacy arrangements.
“The 340B program plays an important public policy role in ensuring access to essential drugs and services for low-income and underserved Americans receiving care at 340B hospitals nationwide,” the report concludes. “Without the program, many patients could have trouble accessing affordable medications and critical health services, jeopardizing their health and well-being.”
Related News Articles
Headline
The House Energy and Commerce Subcommittee on Health May 17 considered a series of health care bills, including a number focused on provisions that would…
Headline
The AHA strongly opposes legislation that would lead to additional site-neutral payment cuts and threaten access to patient care, Ashley Thompson, AHA senior…
Headline
More than 1,000 executive leaders from the nation’s top hospitals and health systems convened at the 2023 AHA Annual Membership Meeting, April 23-25 in…
Headline
The AHA, joined by the Arkansas Hospital Association and 340B Health, late Friday filed an amicus brief in the U.S. Court of Appeals for the 8th Circuit…
Headline
The Pharmaceutical Research and Manufacturers of America’s new ASAP 340B coalition “is another misguided attempt by drug companies to dismantle the 340B Drug…
Blog
Once again, the Pharmaceutical Research and Manufacturers of America (PhRMA) has demonstrated its willingness to put the profits of its drug company members…